NOVOCURE LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 16.61 USD | -1.60% |
|
-14.56% | +11.25% |
| 09-03 | NovoCure CEO Asaf Danziger to Retire, CFO Ashley Cordova Named Successor | MT |
| 09-03 | Novocure Announces CEO Changes, Effective January 1, 2025 | CI |
EPS & Dividend: NovoCure Limited
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | -0.07 | 0.2 | -0.56 | -0.88 | -1.95 | -1.345 | -1.414 | -1.343 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Reference price 2 | 84.27 | 173.04 | 75.08 | 73.35 | 14.93 | 16.61 | 16.61 | 16.61 |
| Nbr of stocks (in thousands) | 98,969 | 101,797 | 103,819 | 104,950 | 106,861 | 108,217 | - | - |
| Announcement Date | 27/02/20 | 25/02/21 | 24/02/22 | 23/02/23 | 22/02/24 | - | - | - |
1USD in Million2USD
Estimates
Upcoming events: NovoCure Limited
More events
| Yield (Y) | Yield (Y+1) | P/E ratio | Price to Book | EV / Sales | ||
|---|---|---|---|---|---|---|
| - | - | - | - | - | ||
| -.--% | -.--% | 268.06x | 6.267 | 6.11x | ||
| - | - | 60.77x | - | 1.88x | ||
| +2.12% | +2.40% | 22.85x | 1.861 | 1.95x | ||
| +0.64% | +0.86% | 46.3x | 5.272 | 6.96x | ||
| +0.53% | +0.69% | 52.58x | 14.33 | - | ||
| +1.99% | +2.14% | 14.29x | 2.344 | - | ||
| -.--% | -.--% | -41.09x | 5.706 | 4.17x | ||
| +0.62% | +0.77% | 50.58x | 8.074 | 4.39x | ||
| Average | +0.84% | +0.98% | 59.29x | 6.27 | 4.24x | |
| Weighted average by Cap. | +0.87% | +1.01% | 80.20x | 6.05 | 4.29x |
Dividend / Share (DPS) - Evolution of Analysts' Estimates
Dividend / Share (DPS) - Estimates Revisions
Estimates Revisions:
More analyst reviews
Earnings Per Share (EPS) - Evolution of Analysts' Estimates
Annual Profit -
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition